Full mechanism, in text

A backup route in liver and kidney

1 · Hcy pool + two exits

Every methylation leaves , a risk if it builds up, so the body clears it by two independent routes: a body-wide main route and a liver and kidney backup. (Hcy) is a byproduct of -driven universal methylation — every time SAM hands a methyl group to DNA / protein / a neurotransmitter, SAM itself becomes SAH → further hydrolyzed to Hcy + adenosine.

Hcy accumulation = risk:

· Cardiovascular-event risk marker (high Hcy ↔ endothelial damage)
· Marker of neuropathy + cognitive decline
· Pregnancy-period high Hcy → miscarriage / neural-tube-defect risk.

So Hcy must be continuously cleared — the body evolved two independent pathways:

Main route (right side, body-wide): MTR + methylcobalamin (B12) + (folate) → Hcy + methyl → methionine (Met).

Backup route (left side, liver/kidney specific): BHMT + betaine () → Hcy + methyl → methionine + DMG.

The two routes are chemically completely different, use completely different enzymes, completely different cofactors — evolution kept the dual-track design because the liver is the largest methylation consumer, so once the main route is constrained (B12 inadequate / folate inadequate / mutation), the liver needs a redundant pathway to maintain methylation flux.

The next three steps light up the main route, the backup route, and the scenario in which the backup becomes dominant after an MTHFR mutation.

2 · Main route

The main route runs in nearly every cell: MTR uses methylcobalamin, a B12 form, to pass the methyl of to and remake methionine, needing both B12 and folate.Main route:

· MTR (methionine synthase) — the reaction core
· Methylcobalamin — the B12 form, the cofactor temporarily carrying the methyl group
· (5-methyl-tetrahydrofolate) — the folate form, the true methyl-group source
· Reaction: + 5-MTHF → Met + THF (+ methylcobalamin recycling).

Main-route characteristics:

· Expressed in nearly every cell in the body — brain / nerves / muscle / red cells / liver / kidney / gut, etc.
· Requires both B12 + folate cofactors to be adequate
· The enzyme converts 5,10-MTHF → 5-MTHF as one of the rate-limiting steps; the MTHFR C677T mutation reduces its activity
· The main route is the 'body-wide coverage' methylation engine.

MTR's chemical chain:

1. 5-MTHF gives the methyl group to the cobalt on MTR → forming methylcobalamin
2. Methylcobalamin gives the methyl to Hcy → forming Met + cob(I)alamin
3. Cob(I)alamin is easily oxidized and inactivated → reactivated by MTRR (methionine synthase reductase) + to cob(II)alamin → ready for the next round.

This is one of the most complex enzymatic reactions in the body — at least 5 different molecules + 2 metal ions involved in one reaction. Any of B12 / folate / MTRR / SAM being inadequate reduces main-route efficiency.

Clinical consequences:

· B12 deficiency (absorption disorders / vegan / older adults) → main route slows → Hcy rises + Met / SAM insufficient → nerve myelin damage
· Folate deficiency (pregnancy + poor diet) → main route slows → neural-tube defects (the basis for folate supplementation in pregnancy)
· MTHFR mutation (C677T) → 5-MTHF insufficient → main route slows → Hcy rises + slight increase in cardiovascular + pregnancy risk.

3 · Backup route

The backup route runs mainly in liver and kidney: BHMT uses a methyl straight from betaine () to turn back into methionine, with no need for B12 or folate.Backup route — this is the heart of the story:

· BHMT (betaine- methyltransferase) — the reaction core
· Betaine (TMG) — the direct methyl donor
· Reaction: Hcy + TMG → Met + DMG (dimethylglycine).

Backup-route characteristics:

· Mainly expressed in liver + kidney — other tissues (brain / nerves / muscle / red cells) express almost no BHMT
· Does not need B12 / folate — entirely independent cofactors
· TMG is a direct methyl donor — one TMG gives one methyl at a time and then becomes DMG (two methyls remaining)
· DMG is further metabolized: DMG can be converted by DMGDH back to sarcosine + methyl → recycled to some degree.

Why evolution gave this only to liver and kidney:

· The liver is the largest methylation consumer:
PEMT pathway: phosphatidylethanolamine → phosphatidylcholine, each reaction consumes 3 methyls — the body's single largest SAM consumerCreatine synthesis (GAMT): GAA + SAM → creatine, accounts for 40-70% of the body's SAM usageBile acids / detoxification / drug metabolism: continuous methylation· Renal osmolyte system: high TMG concentrations used in medullary urinary concentration
· These two organs have the largest methyl demand, and giving them a 'backup power supply' is sound evolutionary design.

Functional division between main and backup routes:

· Main route: body-wide coverage, speed limited by / B12 /
· Backup route: only liver + kidney, speed limited by TMG (diet + endogenous choline synthesis)
· Normal state: main route 50-70% + backup 20-30% (in liver) + backup ≈ 0% (in nerves).

This is a teaching sample of 'two routes in parallel vs one main route' — evolution often designs redundancy for the most important + highest-demand metabolic lines, while not wasting gene expression on low-demand cells (nerves / muscle).

4 · MTHFR + backup dominance

The C677T mutation cuts and weakens the main route, so the BHMT backup, which MTHFR does not affect, matters more, and supplemental feeds it directly.Scenario for C677T carriers:

How common TT homozygosity is (NIH ODS): ~25% of Hispanics, ~10% of Whites and of Asians, ~1% of African Americans.

Main route weakened:

· production insufficient → MTR reaction lacks substrate → main-route flux falls
· When the main route is slow, the liver/kidney backup is relatively more important — a spare track matters more when the main track is constrained, not a genotype-stratified special effect.

Backup route relatively more important:

· BHMT expression is unaffected by MTHFR — the pool determines flow
· Supplementing TMG → directly feeds the backup route. Olthof 2003 did not genotype, so this page does not claim the largest drop in MTHFR carriers.

Clinical data (Olthof 2003): four groups of 19 healthy subjects; 1.5, 3 or 6 g/d betaine or placebo for 6 wk; fasting after 6 wk was 12%, 15%, 20% less than placebo. No CC / CT / TT strata.

What limits the backup route:

· Only resolves liver/kidney Hcy — nervous tissue has no BHMT, so TMG cannot rescue neural B12 deficiency
· Excess TMG → DMG → TMA (gut bacteria) → TMAO — parallel to the choline / red-meat TMAO pathway (the choline story covers that TMAO pathway).

Overall clinical significance:

· The methylation dual-track design is real evolutionary architecture, not 'artificial redundancy'
· Main route constrained → backup more important — the most valuable clinical implication for readers
· TMG is a reasonable option when 5-MTHF/B12 are already in place but Hcy is still high
· Adequate dietary TMG: no supplementation needed.

'Hcy is not a single pathway; main + backup back each other up' — the most direct example of taking 'mechanism → where to intervene' into B vitamins / one-carbon metabolism.

The links in the one-carbon chain: vitamin B12 (main route MTR) + folate (5-MTHF upstream) + betaine (backup route BHMT) + choline (PEMT consumer) + glycine (Gly supply via the SHMT pathway).

Full mechanism, in text

1 · Hcy pool + two exits

2 · Main route

3 · Backup route

4 · MTHFR + backup dominance

Hcy remethylation dual-track

Full mechanism, in text

1 · Hcy pool + two exits

2 · Main route

3 · Backup route

4 · MTHFR + backup dominance

Hcy remethylation dual-track